A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer
详细信息 查看全文
- 作者：Volker Heinemanna ; Volker.Heinemann@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author ; Fernando Riverab ; oncrhf@humv.es" class="auth_mail" title="E-mail the corresponding author ; Bert H. O'Neilc ; bhoneil@iu.edu" class="auth_mail" title="E-mail the corresponding author ; Sebastian Stintzinga ; Sebastian.Stintzing@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author ; Reija Koukakisd ; reijak@amgen.com" class="auth_mail" title="E-mail the corresponding author ; Jan-Henrik Terweye ; jan-henrik.terwey@amgen.com" class="auth_mail" title="E-mail the corresponding author ; Jean-Yves Douillardf ; jean-yves.douillard@esmo.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：Bevacizumab ; Cetuximab ; Panitumumab ; Meta-analysis ; Survival ; Progression-free survival
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：67
- 期：Complete
- 页码：11-20
- 全文大小：462 K
文摘
- •
Three first-line trials compared chemotherapy + epidermal growth factor receptor inhibitor (EGFRI) or bevacizumab in RAS WT mCRC.
- •
Latest data from these trials were included in a study-level meta-analysis.
- •
Meta-analysis showed EGFRI + chemotherapy improved overall survival versus bevacizumab + chemotherapy.
- •
EGFRI + chemotherapy also had benefits in terms of objective response rate and early tumour shrinkage.
- •
Progression-free survival was similar between treatments.